How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Executive Summary
Drug Review Profile examines how Amgen persuaded US agency that its preferred distinguishable suffix choice for Amjevita, a biosimilar to AbbVie’s Humira, would not be confused with medical abbreviations or existing trademarks.
You may also be interested in...
Drug Review Profiles: Behind The Scenes At US FDA
A year in our long-running series of deep dives into FDA review documents.
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.